Bio Platforms

THERAPEUTIC FOCUS – Targeting the Novel LANCL2 Pathway Offers Potential for a Differentiated Treatment Paradigm for Autoimmune Diseases

Andrew Leber, PhD, Raquel Hontecillas, PhD, and Josep Bassaganya-Riera, PhD, say current IBD therapeutics have mediocre efficacy, poor maintenance of response, and damaging side effects, including cancer, infection, and death, resulting in an unmet clinical need for safer and more effective oral therapeutics.

EXCLUSIVE ONLINE CONTENT

9/15/2020

Novus Announces Acquisition of Anelixis

Novus Therapeutics, Inc. recently announced it has completed the acquisition of Anelixis Therapeutics, Inc., a privately held clinical-stage biotechnology company developing a next-generation….